Most clinical research professionals are familiar with FDA’s Office of Orphan Products Development and the provisions of 21 CFR that facilitate the marketing of new treatments for rare health conditions. A lesser-known NIH program called TRND (Therapeutics for Rare and Neglected Diseases) provides a different kind of support for rare disease research. According to a story on the Genetic Engineering & Biotechnology News website, the program has approved a total of 15 projects and two have moved into clinical testing.
